Alto Neuroscience
Update in progressANRO (NYSE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Alto Neuroscience, Inc. is a US-based clinical-stage biopharmaceutical company founded in 2019 and headquartered in Mountain View, California. Its pipeline includes ALTO-100 in Phase 2b for bipolar depression, ALTO-300 in Phase 2b for major depressive disorder, ALTO-101 in Phase 2 for cognitive impairment in schizophrenia, ALTO-203 in Phase 2 POC for MDD with high anhedonia, ALTO-202 in Phase 1 for MDD, and ALTO-208, a fixed-dose pramipexole plus aprepitant NK-1 antagonist for Parkinson's disease.
Company score
- Sentiment
- 0.31
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.16
- Governance
- -0.36
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.03
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.14
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!